Dreavent Capital
VC Fund
Cambridge, United States
Dreavent Capital is an investment firm focused on Biotech Therapeutics companies.
- Total investments:
- 6
- Last investment:
- Lead investor:
- 33%
- Fund size:
- $941k
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Dreavent Capital invests in
Stages Dreavent Capital invests in
Countries Dreavent Capital invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Investment Focus
Industry
- Biotechnology 5 (83%)
- Health Care 3 (50%)
- Therapeutics 2 (33%)
- Pharmaceutical 2 (33%)
- Life Science 1 (17%)
Stage
- Series A 3 (50%)
- Venture - Series Unknown 2 (33%)
- Series B 1 (17%)
Country
- United States 4 (67%)
- Spain 1 (17%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Brian Gallagher
Venture Partner
|
Venture Partner | Total investments: 9 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| A4CELL is a company that develops SPAchip (suspended planar-array chips) that help monitor living single cells. They offer SPAchips, as well as the CytoCHECK SPAchip and the CytoCHECK SPAchip. The company's goal is to increase the accuracy and quality of cell study data in order to better understand disease behavior. | $3.2M / Venture - Series Unknown / Oct 19, 2023 | ||
| Astrocyte Pharmaceuticals Inc. is a privately held drug development company dedicated to accelerating the recovery and well-being of brain injury patients. The company is committed to proving the neuroprotective benefits of selective astrocyte activation, and advancing breakthrough therapeutic agents for treating brain injury resulting from stroke,TBI, concussion, and neurodegenerative disorders such as Alzheimer’s disease. | $6M / Series B / Aug 18, 2023 | ||
| Nido Biosciences is a clinical-stage company that develops precision medicines for severe neurological diseases. Nido Bio is developing solutions for severe neurological illnesses based on today's advances in neuroscience. The company creates precise medications using human genetics that treat the underlying biology of disease and restorehealthy cell function. | $18.4M / Series A / Sep 08, 2020 | ||
| Aardvark Therapeutics specializes in small molecule therapeutics for obesity and rare genetic metabolic disorders. Aardvark Therapeutics was founded by Tien Lee in 2017. | $15M / Series A / Nov 29, 2019 | ||
Chimeron Bio
|
Venture - Series Unknown / Jan 01, 2018 | ||
| Inspirna (formerly Rgenix) is a clinical-stage biopharmaceutical company developing first-in-class/best-in-class drug candidates that target critical cancer drivers. Our discovery platform leverages RNA biology to discover novel RNA dysregulated cancer drivers that can be targeted by small molecules and biologics. Clinical programs arefirst-in-class oral small molecules in development for patients with RAS mutant CRC (RGX-202; Phase 1b) as well as SCLC and NSCLC (RGX-104; Phase 1b/2) | $8M / Series A / Aug 18, 2015 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Dreavent Capital invest in?
Dreavent Capital invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Venture - Series Unknown stage. Most of the 6 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Dreavent Capital?
Public channels for Dreavent Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Dreavent Capital?
The team at Dreavent Capital includes Brian Gallagher (Venture Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
